These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11158196)

  • 1. Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death.
    Blagosklonny MV
    J Natl Cancer Inst; 2001 Feb; 93(3):239-40. PubMed ID: 11158196
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture.
    Freedman DA; Levine AJ
    Cancer Res; 1999 Jan; 59(1):1-7. PubMed ID: 9892174
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of the heat shock response and molecular chaperones in oncogenesis and cell death.
    Jolly C; Morimoto RI
    J Natl Cancer Inst; 2000 Oct; 92(19):1564-72. PubMed ID: 11018092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2: the ups and downs.
    Juven-Gershon T; Oren M
    Mol Med; 1999 Feb; 5(2):71-83. PubMed ID: 10203572
    [No Abstract]   [Full Text] [Related]  

  • 5. Mdm2: keeping p53 under control.
    Piette J; Neel H; Maréchal V
    Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
    Wawrzynow B; Zylicz A; Zylicz M
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
    Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumorogenesis and mdm2 protein].
    Flores C; Sobrevia L
    Rev Med Chil; 2000 May; 128(5):539-46. PubMed ID: 11008360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher-grade transformation of follicular lymphoma -- a continuous enigma.
    Lossos IS
    Leukemia; 2005 Aug; 19(8):1331-3. PubMed ID: 15902286
    [No Abstract]   [Full Text] [Related]  

  • 11. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
    Soufla G; Baritaki S; Sifakis S; Zafiropoulos A; Spandidos DA
    Int J Biol Markers; 2005; 20(1):18-27. PubMed ID: 15832769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.
    Jones SN; Sands AT; Hancock AR; Vogel H; Donehower LA; Linke SP; Wahl GM; Bradley A
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14106-11. PubMed ID: 8943068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.
    Dubs-Poterszman MC; Tocque B; Wasylyk B
    Oncogene; 1995 Dec; 11(11):2445-9. PubMed ID: 8570197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of p53 ubiquitination and nuclear export by MDM2 and ARF.
    Zhang Y; Xiong Y
    Cell Growth Differ; 2001 Apr; 12(4):175-86. PubMed ID: 11331246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.
    Ramos YF; Stad R; Attema J; Peltenburg LT; van der Eb AJ; Jochemsen AG
    Cancer Res; 2001 Mar; 61(5):1839-42. PubMed ID: 11280734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
    Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
    Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
    Capoulade C; Bressac-de Paillerets B; Lefrère I; Ronsin M; Feunteun J; Tursz T; Wiels J
    Oncogene; 1998 Mar; 16(12):1603-10. PubMed ID: 9569028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.
    Lin J; Jin X; Page C; Sondak VK; Jiang G; Reynolds RK
    Cancer Res; 2000 Oct; 60(20):5895-901. PubMed ID: 11059788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells.
    Gudas JM; Nguyen H; Klein RC; Katayose D; Seth P; Cowan KH
    Clin Cancer Res; 1995 Jan; 1(1):71-80. PubMed ID: 9815889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.